Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00888043 | Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors(CNTO95/Avastin) | completed | Phase 1 | 13 | Herbert Hurwitz, MDOTHER | 1 | Mar 11, 2015 | clinicaltrials |
| NCT01234012 | Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 | completed | Phase 1 | 23 | ImmunoFrontier, Inc.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00352443 |
| S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
| completed |
| Phase 1 |
| 66 |
| SWOG Cancer Research NetworkNETWORK |
| 1 |
| Mar 6, 2015 |
| clinicaltrials |
| NCT00788580 | S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Mar 6, 2015 | clinicaltrials |
| NCT01324115 | NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 6 | Cancer Research UKOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01137552 | A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors | terminated | Phase 1 | 44 | AmgenINDUSTRY | 1 | Mar 4, 2015 | clinicaltrials |
| NCT00704054 | A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) | completed | Phase 1 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00781846 | Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | completed | Phase 1 | 17 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT02049281 | A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011) | terminated | Phase 1 | 3 | EndocyteINDUSTRY | 0 | Feb 10, 2015 | clinicaltrials |
| NCT01417403 | Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases | terminated | Phase 1 | 10 | Virginia Commonwealth UniversityOTHER | 1 | Feb 3, 2015 | clinicaltrials |
| NCT01844869 | An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | completed | Phase 1 | 6 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 1 | Jan 30, 2015 | clinicaltrials |
| NCT00818831 | A Study of QBI-139 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 30 | Quintessence Biosciences, Inc.INDUSTRY | 1 | Jan 28, 2015 | clinicaltrials |
| NCT00879684 | Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors | completed | Phase 1 | 34 | PfizerINDUSTRY | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00635596 | Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer(MT110-101) | completed | Phase 1 | 65 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 13, 2015 | clinicaltrials |
| NCT00665990 | Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | completed | Phase 1 | 49 | St. Jude Children's Research HospitalOTHER | 1 | Jan 9, 2015 | clinicaltrials |
| NCT02048943 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01218620 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00354523 | Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 17, 2014 | clinicaltrials |
| NCT00813384 | A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 54 | AmgenINDUSTRY | 1 | Dec 16, 2014 | clinicaltrials |
| NCT00217477 | Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer | completed | Phase 1 | 34 | Roswell Park Cancer InstituteOTHER | 1 | Dec 9, 2014 | clinicaltrials |
| NCT00984425 | The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors | completed | Phase 1 | 30 | Istituto Clinico HumanitasOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00276575 | Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 65 | Herbert Hurwitz, MDOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00586443 | BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)(BEP) | completed | Phase 1 | 56 | Herbert Hurwitz, MDOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00667147 | Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib | completed | Phase 1 | 65 | University of Southern CaliforniaOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01165385 | Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors(PACIFIK) | completed | Phase 1 | 35 | UNICANCEROTHER | 1 | Nov 17, 2014 | clinicaltrials |
| NCT01238939 | Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer | completed | Phase 1 | 35 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01238952 | Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer | completed | Phase 1 | 4 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT02033148 | Icotinib Hydrochloride in Treating Patients With Advanced Cancers | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Nov 5, 2014 | clinicaltrials |
| NCT00914914 | Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment | completed | Phase 1 | 15 | Dr. Tapas K. Das GuptaINDUSTRY | 1 | Oct 28, 2014 | clinicaltrials |
| NCT01164163 | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | completed | Phase 1 | 49 | Children's Oncology GroupNETWORK | 1 | Oct 23, 2014 | clinicaltrials |
| NCT01245205 | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2014 | clinicaltrials |
| NCT01919866 | Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells | unknown | Phase 1 / Phase 2 | 120 | University Children's Hospital TuebingenOTHER | 2 | Oct 8, 2014 | clinicaltrials |
| NCT01762410 | Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors | suspended | Phase 1 | 60 | Piramal Enterprises LimitedINDUSTRY | 2 | Sep 29, 2014 | clinicaltrials |
| NCT01779336 | Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors | suspended | Phase 1 | 70 | Piramal Enterprises LimitedINDUSTRY | 2 | Sep 29, 2014 | clinicaltrials |
| NCT01835184 | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01992341 | AMG 386 Drug-Drug Interaction Study With Paclitaxel | completed | Phase 1 | 35 | AmgenINDUSTRY | 1 | Sep 23, 2014 | clinicaltrials |
| NCT00968916 | Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors | completed | Phase 1 | 15 | SanofiINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01279603 | Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas | completed | Phase 1 | 23 | Genus Oncology, LLCINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00687934 | Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors | completed | Phase 1 | 53 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00688116 | Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors | unknown | Phase 1 | 45 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00004258 | EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer | completed | Phase 1 | 40 | Indiana UniversityOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT01702129 | Anti-EGFR Immunoliposomes in Solid Tumors | completed | Phase 1 | 26 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 9, 2014 | clinicaltrials |
| NCT00057915 | Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer | completed | Phase 1 | 4 | Duke UniversityOTHER | 1 | Sep 8, 2014 | clinicaltrials |
| NCT00275080 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2014 | clinicaltrials |
| NCT00720148 | A Phase I Trial of Bortezomib and Sunitinib | completed | Phase 1 | 30 | Emory UniversityOTHER | 1 | Aug 26, 2014 | clinicaltrials |
| NCT01392976 | Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Clovis Oncology, Inc.INDUSTRY | 1 | Aug 15, 2014 | clinicaltrials |
| NCT01313065 | Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Vaccinex Inc.INDUSTRY | 1 | Aug 13, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Mar 11, 2015source: clinicaltrials